GlassScriptPhysician profile
Kyle P Riganati
NPI 1407111404
$8,738.31
in general payments reported to CMS, 2019-2025
42 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $306 · 2021: $793 · 2022: $1,424 · 2023: $1,690 · 2024: $1,631 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,611.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,118.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $963.17 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $927.52 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Lilly USA, LLC | $819.13 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $603.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $520.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.10 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $315.23 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $266.98 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.36 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $239.62 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $218.13 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $178.39 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $177.43 | 2022 | |
| Amarin Pharma, INC. | $175.47 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Riganati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.